Floatz logo

ds-5565

Postherpetic Neuralgia

Daiichi Sankyo Co., Ltd.Phase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

19 Active assets in the Postherpetic Neuralgia cohort.

Asset / SponsorPhaseRating
LIDOCAINE
Seoul National University Hospital
Phase 4BBB
Pregabalin
Neurodawn Pharmaceutical Co., Ltd.
Phase 4BBB
CYCLOHEXANEACETIC ACID, 1-(AMINOMETHYL)-
University of Medicine and Pharmacy at Ho Chi Minh City
Phase 4BBB
Capsaicin
Astellas Pharma Europe Ltd.
Phase 4BBB
Crisugabalin
Haisco Pharmaceutical Group Co., Ltd.
Phase 3BB

View all 50 →

Same molecule, other indications

ds-5565 is also rated in:

diabetic neuropathyDormant
BBB
Indicative ·
79 / 100
View asset →
Central Neuropathic PainDormant
BB
Indicative ·
64 / 100
View asset →
fibromyalgiaDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →